- Home
- KURA vs CARE Comparison
KURA vs CARE Comparison
Compare KURA & CARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | CARE |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 723.5M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KURA | CARE |
|---|---|---|
| Price | $10.40 | $33.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $25.56 | $25.00 |
| AVG Volume (30 Days) | ★ 1.4M | 371.0K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.40% |
| EPS Growth | N/A | ★ 30.19 |
| EPS | N/A | ★ 3.88 |
| Revenue | ★ $67,482,000.00 | $20,315,000.00 |
| Revenue This Year | $28.28 | $12.50 |
| Revenue Next Year | $106.37 | $11.82 |
| P/E Ratio | ★ N/A | $8.78 |
| Revenue Growth | ★ 25.24 | 4.65 |
| 52 Week Low | $5.45 | $16.78 |
| 52 Week High | $12.49 | $35.14 |
Technical Indicators
Market Signals| Indicator | KURA | CARE |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 64.64 |
| Support Level | $8.53 | $31.29 |
| Resistance Level | $10.97 | $35.03 |
| Average True Range (ATR) | 0.47 | 1.04 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 10.29 | 71.43 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About CARE Carter Bankshares Inc.
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.